GSK plc
GSK
$40.70
$0.651.62%
| Weiss Ratings | GSK - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Fair | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | C+ | |||
| Rating Factors | GSK - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | Fair | |||
| Growth Index | Fair | |||
| Efficiency Index | Excellent | |||
| Solvency Index | Good | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | GSK - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.40 | |||
| Price History | GSK - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 9.03% | |||
| 30-Day Total Return | 19.95% | |||
| 60-Day Total Return | 14.21% | |||
| 90-Day Total Return | 10.75% | |||
| Year to Date Total Return | 21.08% | |||
| 1-Year Total Return | -1.96% | |||
| 2-Year Total Return | 30.94% | |||
| 3-Year Total Return | 12.22% | |||
| 5-Year Total Return | 22.34% | |||
| 52-Week High % Change | -12.79% | |||
| 52-Week Low % Change | 26.28% | |||
| Price | GSK - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $45.93 | |||
| 52-Week Low Price | $31.72 | |||
| 52-Week Low Price (Date) | Jan 14, 2025 | |||
| 52-Week High Price (Date) | May 15, 2024 | |||
| Valuation | GSK - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 80.77B | |||
| Enterprise Value | 96.37B | |||
| Price/Earnings (TTM) | 50.57 | |||
| Earnings Per Share (TTM) | 0.79 | |||
| Earnings Per Share Growth | -47.11% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 4.14 | |||
| Price/Book (Q) | 9.55 | |||
| Enterprise Value/Revenue (TTM) | 2.40 | |||
| Price | $40.67 | |||
| Enterprise Value/EBITDA (TTM) | 8.60 | |||
| Enterprise Value/EBIT | 12.37 | |||
| Market Cap Category | Large Cap | |||
| Dividends and Shares | GSK - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 4.15B | |||
| Dividend Yield | 3.81% | |||
| Div. Per Share (Most Recent) | $0.39 | |||
| Dividend Per Share (TTM) | $1.52 | |||
| Payout Ratio (TTM) | 95.77% | |||
| Dividend Per Share (Most Recent) | $0.39 | |||
| Company Info | GSK - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 44 20 8047 5000 | |||
| Address | -- | |||
| Website | www.gsk.com | |||
| Country | United Kingdom | |||
| Year Founded | 1715 | |||
| Profitability | GSK - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 19.42% | |||
| Profit Margin | 8.13% | |||
| Management Effectiveness | GSK - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | 6.51% | |||
| Return on Equity | 22.90% | |||
| Income Statement | GSK - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 40.10B | |||
| Total Revenue (TTM) | 40.10B | |||
| Revenue Per Share | $9.68 | |||
| Gross Profit (TTM) | 28.80B | |||
| EBITDA (TTM) | 11.21B | |||
| EBIT (TTM) | 7.79B | |||
| Net Income (TTM) | 3.26B | |||
| Net Income Avl. to Common (TTM) | 3.26B | |||
| Total Revenue Growth (Q YOY) | 3.93% | |||
| Earnings Growth (Q YOY) | 29.78% | |||
| EPS Diluted (TTM) | 0.79 | |||
| EPS Diluted Growth (Q YOY) | 20.94% | |||
| Balance Sheet | GSK - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 5.42B | |||
| Cash Per Share (Q) | $1.31 | |||
| Total Current Assets (Q) | 21.28B | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 16.38B | |||
| Current Ratio (Q) | 0.783 | |||
| Book Value Per Share (Q) | $4.19 | |||
| Total Assets (Q) | 74.44B | |||
| Total Current Liabilities (Q) | 27.16B | |||
| Total Debt (Q) | 21.27B | |||
| Total Liabilities (Q) | 58.06B | |||
| Total Common Equity (Q) | 17.12B | |||
| Cash Flow | GSK - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -1.60B | |||
| Cash from Financing (TTM) | -6.03B | |||
| Net Change in Cash (TTM) | 698.87M | |||
| Levered Free Cash Flow (TTM) | 6.26B | |||
| Cash from Operations (TTM) | 8.40B | |||
